Results 111 to 120 of about 5,026 (198)

Reduction in Synaptic Vesicle Protein Abundance but Increased Amounts of Nsg2 and Lpcat1 in Cerebral Cortices Without the Endosomal SNARE Proteins Vti1a and Vti1b

PROTEOMICS, Volume 26, Issue 5, Page 86-97, May 2026.
ABSTRACT Absence of the endosomal SNAREs vti1a and vti1b results in perinatal death and severe neuronal phenotypes in mice, while lack of one of these proteins results in minor phenotypes. Proteomic differences were investigated to obtain a deeper insight into processes in which vti1a and vti1b are involved.
Julia Gottschalk, Katharina Kotschnew, Julia Hahn, Thomas Patschkowski, Gabriele von Fischer von Mollard   +4 more
wiley   +1 more source

Myasthenia gravis: the future is here

The Journal of Clinical Investigation
Myasthenia gravis (MG) stands as a prototypical antibody-mediated autoimmune disease: it is dependent on T cells and characterized by the presence of autoantibodies targeting proteins located on the postsynaptic surface of skeletal muscle, known as the ...
Henry J. Kaminski, Patricia Sikorski, S. Isabel Coronel, Linda L. Kusner   +3 more
doaj   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity‐MG3 Study

European Journal of Neurology, Volume 33, Issue 5, May 2026.
In the Vivacity‐MG3 study, clinical response to nipocalimab was assessed using the MG‐ADL and QMG measures. Nipocalimab treatment improves gMG symptoms earlier than placebo and provides sustained disease control over the 24‐week double‐blind period.
Tuan Vu, Said R. Beydoun, Richard J. Nowak, Hans Katzberg, Maria Ait‐Tihyaty, Kavita Gandhi, John J. Sheehan, Sheryl Pease, Ibrahim Turkoz, Bernie Sattin, Zia Choudhry, Sindhu Ramchandren, Carlo Antozzi   +12 more
wiley   +1 more source

Nanomedicines for renal disease: current status and future applications [PDF]

, 2016
Ausiello, Dennis A., Farokhzad, Omid C., He, John C., Kamaly, Nazila   +3 more
core   +1 more source

Solution behaviour of Human Serum Albumin and GLP-1variants [PDF]

, 2016
Sønderby, Pernille
core  

FcRn Inhibitor Combination with C5 Complement Blockade for Refractory MG

Dual targeting of FcRn (FCGRT, Open Targets score 0.59) and complement C5 (score 0.57) addresses both pathogenic antibody recycling and complement-mediated neuromuscular junction damage. ChEMBL compounds CHEMBL508564 and CHEMBL508411 target FCGRT, while existing drugs like eculizumab target C5.
openaire   +1 more source

Polypharmacology of S-1117, an Fc-fused IgG-selective degrading enzyme, for chronic treatment of autoantibody-mediated diseases. [PDF]

Proc Natl Acad Sci U S A
Sanmarco LM, Pellerin A, Green T, Plasencia A, Anderson JM, Le N, Newton A, Chen J, Ramello MC, Peckner R, Manasson J, Xing Y, Vital H, Higginson-Scott N, Sundy JS, Otipoby KL, Mascanfroni ID.   +16 more
europepmc   +1 more source

Current status and challenges of biologic targeted therapy for myasthenia gravis in China. [PDF]

Intractable Rare Dis Res
Gu S, Zhao C.
europepmc   +1 more source

The Effect of FcRn Binding on Ocular Disposition of Monoclonal Antibodies. [PDF]

Antibodies (Basel)
Naware S, Kulkarni S, Salvi S, Patel D, Shah DK.   +4 more
europepmc   +1 more source